Brain muscarinic cholinergic receptors in Huntington's disease
- PMID: 1532417
- DOI: 10.1007/BF00862983
Brain muscarinic cholinergic receptors in Huntington's disease
Abstract
Muscarinic cholinergic receptors and choline acetyltransferase (ChAT) activity were studied in postmortem brain tissue from patients with Huntington's disease and matched control subjects. In comparison with controls, reductions in ChAT activity were found in the hippocampus, but not in the temporal cortex in Huntington's disease. Patients with Huntington's disease showed reduced densities of the total number of muscarinic receptors and of M-2 receptors in the hippocampus while the density of M-1 receptors was unaltered. Muscarinic receptor binding was unchanged in the temporal cortex. These results indicate a degeneration in Huntington's disease of the septo-hippocampal cholinergic pathway, but no impairment of the innominato-cortical cholinergic system.
Similar articles
-
Alterations in brain muscarinic cholinergic receptor binding and choline acetyltransferase activity in Huntington's disease.Proc West Pharmacol Soc. 1976;19:170-1. Proc West Pharmacol Soc. 1976. PMID: 136659 No abstract available.
-
Age-related differences in brain choline acetyltransferase, cholinesterases and muscarinic receptor sites in two strains of rats.Neurobiol Aging. 1989 Mar-Apr;10(2):143-8. doi: 10.1016/0197-4580(89)90023-7. Neurobiol Aging. 1989. PMID: 2725809
-
Huntington's disease: regional alteration in muscarinic cholinergic receptor binding in human brain.Life Sci. 1976 Oct 1;19(7):1033-9. doi: 10.1016/0024-3205(76)90295-2. Life Sci. 1976. PMID: 136582 No abstract available.
-
Advances and limitations of the molecular neuroanatomy of cholinergic receptors: the example of multiple muscarinic receptors.Prog Brain Res. 1993;98:95-101. doi: 10.1016/s0079-6123(08)62385-7. Prog Brain Res. 1993. PMID: 8248542 Review. No abstract available.
-
Neurobiology and pharmacology of Huntington's disease.Life Sci. 1977 Jan 15;20(2):205-11. doi: 10.1016/0024-3205(77)90314-9. Life Sci. 1977. PMID: 190505 Review. No abstract available.
Cited by
-
Reduction of [11C](+)3-MPB binding in brain of chronic fatigue syndrome with serum autoantibody against muscarinic cholinergic receptor.PLoS One. 2012;7(12):e51515. doi: 10.1371/journal.pone.0051515. Epub 2012 Dec 11. PLoS One. 2012. PMID: 23240035 Free PMC article.
-
RE1-silencing transcription factor controls the acute-to-chronic neuropathic pain transition and Chrm2 receptor gene expression in primary sensory neurons.J Biol Chem. 2018 Dec 7;293(49):19078-19091. doi: 10.1074/jbc.RA118.005846. Epub 2018 Oct 16. J Biol Chem. 2018. PMID: 30327427 Free PMC article.
-
M1 muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons.Neuropharmacology. 2017 May 15;118:209-222. doi: 10.1016/j.neuropharm.2017.03.017. Epub 2017 Mar 20. Neuropharmacology. 2017. PMID: 28336323 Free PMC article.
-
Genistein improves 3-NPA-induced memory impairment in ovariectomized rats: impact of its antioxidant, anti-inflammatory and acetylcholinesterase modulatory properties.PLoS One. 2015 Feb 12;10(2):e0117223. doi: 10.1371/journal.pone.0117223. eCollection 2015. PLoS One. 2015. PMID: 25675218 Free PMC article.
-
Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease.J Huntingtons Dis. 2016 Dec 15;5(4):333-342. doi: 10.3233/JHD-160200. J Huntingtons Dis. 2016. PMID: 27983560 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical